Ilsung Pharm (003120) - Total Assets
Based on the latest financial reports, Ilsung Pharm (003120) holds total assets worth ₩402.93 Billion KRW (≈ $273.06 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ilsung Pharm - Total Assets Trend (2013–2025)
This chart illustrates how Ilsung Pharm's total assets have evolved over time, based on quarterly financial data. Also see Ilsung Pharm market cap and net worth for the company's overall valuation and market capitalisation.
Ilsung Pharm - Asset Composition Analysis
Current Asset Composition (December 2025)
Ilsung Pharm's total assets of ₩402.93 Billion consist of 67.0% current assets and 33.0% non-current assets. Review 003120 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 29.9% |
| Accounts Receivable | ₩16.28 Billion | 4.0% |
| Inventory | ₩26.50 Billion | 6.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.63 Billion | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Ilsung Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 003120 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ilsung Pharm's current assets represent 67.0% of total assets in 2025, an increase from 37.1% in 2013.
- Cash Position: Cash and equivalents constituted 29.9% of total assets in 2025, up from 1.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 6.6% of total assets.
Ilsung Pharm Competitors by Total Assets
Key competitors of Ilsung Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Ilsung Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.24 | 14.37 | 13.34 |
| Quick Ratio | 11.05 | 12.82 | 12.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩249.01 Billion | ₩254.26 Billion | ₩263.00 Billion |
Ilsung Pharm - Advanced Valuation Insights
This section examines the relationship between Ilsung Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.39 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.5% |
| Total Assets | ₩403.01 Billion |
| Market Capitalization | $105.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ilsung Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ilsung Pharm's assets grew by 1.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ilsung Pharm (2013–2025)
The table below shows the annual total assets of Ilsung Pharm from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩403.01 Billion ≈ $273.11 Million |
+1.54% |
| 2024-12-31 | ₩396.88 Billion ≈ $268.96 Million |
-5.32% |
| 2023-12-31 | ₩419.19 Billion ≈ $284.08 Million |
-15.22% |
| 2022-12-31 | ₩494.42 Billion ≈ $335.06 Million |
+33.13% |
| 2021-12-31 | ₩371.38 Billion ≈ $251.68 Million |
+0.04% |
| 2020-12-31 | ₩371.22 Billion ≈ $251.57 Million |
+0.46% |
| 2019-12-31 | ₩369.52 Billion ≈ $250.42 Million |
+6.41% |
| 2018-12-31 | ₩347.26 Billion ≈ $235.34 Million |
-0.06% |
| 2017-12-31 | ₩347.46 Billion ≈ $235.47 Million |
+2.65% |
| 2016-12-31 | ₩338.50 Billion ≈ $229.40 Million |
-7.77% |
| 2015-12-31 | ₩367.03 Billion ≈ $248.73 Million |
-3.00% |
| 2014-12-31 | ₩378.37 Billion ≈ $256.42 Million |
+1.53% |
| 2013-12-31 | ₩372.66 Billion ≈ $252.55 Million |
-- |
About Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more